Last reviewed · How we verify
NCT05438251
Exploring the Effect of Fespixon Cream for the Treatment of Diabetic Foot Ulcers (TEXAS 3A, 3B)
Phase 4 trial testing Fespixon Cream in Diabetic Foot Ulcer (DFU) in 3 participants. Terminated before completion.
3 April 2024
Quick facts
| Lead sponsor | Oneness Biotech Co., Ltd. |
|---|---|
| Phase | Phase 4 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 3 |
| Start date | 4 August 2022 |
| Primary completion | 3 April 2024 |
| Estimated completion | 3 April 2024 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- Fespixon Cream — full drug profile →
Conditions studied
- Diabetic Foot Ulcer (DFU) — all drugs for Diabetic Foot Ulcer (DFU) →
Sponsor
Oneness Biotech Co., Ltd. — full company profile →
Who can join
Adults 20 to 80, any sex, with Diabetic Foot Ulcer (DFU). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Research Study to evaluate the therapeutic effect of Fespixon cream in patients suffering from DFU (UTWCS Grade III-A or III-B) by measuring the change of grade of UTWCS (University of Texas Diabetic Wound Classification system), wound area reduction, infection control, and incidence of treatment-emergent adverse event (TEAE).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05438251
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Fespixon Cream
Trials testing the same drug.
- NCT05317442 — Open-label Study to Evaluate the Efficacy and Safety of Fespixon Cream for the Treatment of Pressure Injury in Sacrum an · Phase 4 · terminated
- NCT05338463 — Fespixon Cream for the Treatment of Chronic Diabetic Foot Ulcers (TEXAS 1A, 2A) in Dialysis Patients · Phase 4 · completed
Other recruiting trials for Diabetic Foot Ulcer (DFU)
Currently open trials in the same condition.
- NCT07498218 — Phase 1 Study of VELGRAFT, a Living Cellular Construct, in the Management of Chronic Diabetic Foot Ulcers Which Have Att · Phase 1 · recruiting
- NCT07172893 — A Non-Randomized Open Label Clinical Trial Evaluating DermaBind TL · Phase 4 · recruiting
- NCT07046767 — CAMP RWE Trial: Amnion Grafts for Healing Hard-to-Heal Ulcers in RW Populations · NA · recruiting
- NCT07116174 — A Prospective Clinical Study to Evaluate the Effectiveness and Safety of Xcell Amnio MatrixTM (XAM) in the Management of · NA · recruiting
- NCT07209475 — Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers. · Phase 4 · recruiting
Other Oneness Biotech Co., Ltd. trials
Trials by the same sponsor.
- NCT06397911 — Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis · Phase 2 · recruiting
- NCT05941793 — A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients · Phase 2 · completed
- NCT05952986 — A Study to Evaluate the Safety and Bridging PK Profile of FB825 for Single Subcutaneous Administration in Healthy Adults · Phase 1 · unknown
- NCT05677893 — A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inh · Phase 1 · completed
- NCT05135130 — Retrospective Record-review Study in Patients Who Had Diabetic Foot Ulcer · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05438251 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Oneness Biotech Co., Ltd.
- Last refreshed: 16 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05438251.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing